93 related articles for article (PubMed ID: 15256457)
1. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.
De Lorenzo C; Arciello A; Cozzolino R; Palmer DB; Laccetti P; Piccoli R; D'Alessio G
Cancer Res; 2004 Jul; 64(14):4870-4. PubMed ID: 15256457
[TBL] [Abstract][Full Text] [Related]
2. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
De Lorenzo C; Di Malta C; Calì G; Troise F; Nitsch L; D'Alessio G
FEBS Lett; 2007 Jan; 581(2):296-300. PubMed ID: 17208233
[TBL] [Abstract][Full Text] [Related]
3. A novel human antitumor dimeric immunoRNase.
Riccio G; Borriello M; D'Alessio G; De Lorenzo C
J Immunother; 2008 Jun; 31(5):440-5. PubMed ID: 18463541
[TBL] [Abstract][Full Text] [Related]
4. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
6. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
[TBL] [Abstract][Full Text] [Related]
9. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells.
Fantin VR; Berardi MJ; Babbe H; Michelman MV; Manning CM; Leder P
Cancer Res; 2005 Aug; 65(15):6891-900. PubMed ID: 16061673
[TBL] [Abstract][Full Text] [Related]
10. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.
De Lorenzo C; Nigro A; Piccoli R; D'Alessio G
FEBS Lett; 2002 Apr; 516(1-3):208-12. PubMed ID: 11959134
[TBL] [Abstract][Full Text] [Related]
11. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
[TBL] [Abstract][Full Text] [Related]
12. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
14. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
De Lorenzo C; D'Alessio G
FEBS J; 2009 Mar; 276(6):1527-35. PubMed ID: 19220462
[TBL] [Abstract][Full Text] [Related]
15. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
17. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
18. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
19. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
Erickson HA; Jund MD; Pennell CA
Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]